The Journal of clinical investigation · 2026
SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Huayi, De Santis Maria Chiara, Tucci Francesco A, Tosoni Daniela, Zhang Ping, Jenkins Meredith L, Villari Giulia, Filippone Maria Grazia, Guerrera Elisa, Tealdi Simone, Gozzelino Luca, Gulluni Federico, Prever Lorenzo, Zanini Cristina, Forni Marco, Franco Irene, Martini Miriam, Burke John E, Serini Guido, Campa Carlo Cosimo, Pece Salvatore, Margaria Jean Piero, Hirsch Emilio
Аннотация
Metastatic progression in aggressive breast cancer (BC) depends on a tightly controlled vesicular recycling network regulated by RAB11, a small guanosine triphosphate enzyme (GTPase). In a cohort of more than 1,000 patients with BC, we identified SH3BP5L as the most highly expressed guanine nucleotide exchange factor (GEF) for RAB11A. High SH3BP5L expression marked an advanced tumor stage, distant metastasis, and poor prognosis, with significant associations in human epidermal growth factor receptor 2-positive (HER2+) and triple-negative breast cancer (TNBC). Using Förster resonance energy transfer (FRET) sensors and artificial intelligence- (AI-assisted) microscopy, we showed that cargo delivery to the plasma membrane required SH3BP5L-dependent activation of RAB11A and assembly of a complex with the anterograde motor KIF5B. This trafficking governed key metastatic features of TNBC, including β1 integrin recycling and α3β1 integrin surface exposure. Inhibition of SH3BP5L or its GEF activity reduced cell spreading in zebrafish and lung metastasis in mouse models, revealing a previously unidentified driver of BC dissemination and a potential therapeutic vulnerability.